AstraZeneca and FibroGen Inc. presented pooled efficacy and cardiovascular (CV) safety analyses from the pivotal Phase III program assessing roxadustat for the treatment of patients with anemia from chronic kidney disease (CKD).
Myovant Sciences’ combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.
